Longitudinal Monitoring of Intra-Tumoural Heterogeneity Using Optical Barcoding of Patient-Derived Colorectal Tumour Models.
cell culture techniques
cell lineage
clonal evolution
colorectal neoplasms
longitudinal imaging
metastasis
neoplasm recurrence
organoids
self-renewal
tumour heterogeneity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Jan 2022
24 Jan 2022
Historique:
received:
22
12
2021
revised:
16
01
2022
accepted:
19
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Geno- and phenotypic heterogeneity amongst cancer cell subpopulations are established drivers of treatment resistance and tumour recurrence. However, due to the technical difficulty associated with studying such intra-tumoural heterogeneity, this phenomenon is seldom interrogated in conventional cell culture models. Here, we employ a fluorescent lineage technique termed "optical barcoding" (OBC) to perform simultaneous longitudinal tracking of spatio-temporal fate in 64 patient-derived colorectal cancer subclones. To do so, patient-derived cancer cell lines and organoids were labelled with discrete combinations of reporter constructs, stably integrated into the genome and thus passed on from the founder cell to all its clonal descendants. This strategy enables the longitudinal monitoring of individual cell lineages based upon their unique optical barcodes. By designing a novel panel of six fluorescent proteins, the maximum theoretical subpopulation resolution of 64 discriminable subpopulations was achieved, greatly improving throughput compared with previous studies. We demonstrate that all subpopulations can be purified from complex clonal mixtures via flow cytometry, permitting the downstream isolation and analysis of any lineages of interest. Moreover, we outline an optimized imaging protocol that can be used to image optical barcodes in real-time, allowing for clonal dynamics to be resolved in live cells. In contrast with the limited intra-tumour heterogeneity observed in conventional 2D cell lines, the OBC technique was successfully used to quantify dynamic clonal expansions and contractions in 3D patient-derived organoids, which were previously demonstrated to better recapitulate the heterogeneity of their parental tumour material. In summary, we present OBC as a user-friendly, inexpensive, and high-throughput technique for monitoring intra-tumoural heterogeneity in in vitro cell culture models.
Identifiants
pubmed: 35158849
pii: cancers14030581
doi: 10.3390/cancers14030581
pmc: PMC8833441
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Health and Medical Research Council
ID : GNT1164081
Organisme : Tour de Cure Foundation, Australia
ID : Senior Research Grant
Références
Nat Med. 2006 Apr;12(4):401-9
pubmed: 16582916
Science. 2013 Feb 1;339(6119):543-8
pubmed: 23239622
Clin Exp Metastasis. 2018 Apr;35(4):333-345
pubmed: 29335811
Cancer. 2013 Aug 15;119(16):3034-42
pubmed: 23696076
J Clin Oncol. 2013 Nov 1;31(31):3898-905
pubmed: 24062393
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):95-100
pubmed: 28069394
EMBO Rep. 2014 Jan;15(1):62-9
pubmed: 24355609
Nat Commun. 2019 Feb 15;10(1):766
pubmed: 30770823
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Cancer Sci. 2014 Jul;105(7):897-904
pubmed: 24815991
Nat Med. 2011 Apr;17(4):504-9
pubmed: 21441917
Nat Methods. 2013 Jun;10(6):540-7
pubmed: 23866336
Mol Ther. 2017 Mar 1;25(3):621-633
pubmed: 28109958
Gene. 1992 Feb 15;111(2):229-33
pubmed: 1347277
Stem Cell Res Ther. 2020 Mar 5;11(1):105
pubmed: 32138773
Cell. 2016 Nov 17;167(5):1310-1322.e17
pubmed: 27863245
Development. 2014 Apr;141(7):1589-98
pubmed: 24644261
Sci Adv. 2021 Jul 7;7(28):
pubmed: 34233875
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Blood. 2010 Apr 1;115(13):2610-8
pubmed: 20093403
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6140-6145
pubmed: 30850544
Nature. 2007 Nov 1;450(7166):56-62
pubmed: 17972876
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Science. 2005 May 20;308(5725):1171-4
pubmed: 15905401
Mol Ther Methods Clin Dev. 2017 Jun 01;6:54-65
pubmed: 28664166
Oncotarget. 2016 Mar 1;7(9):10051-63
pubmed: 26840267
Biochem Soc Trans. 2019 Aug 30;47(4):1117-1129
pubmed: 31278154
Cell. 2010 Oct 1;143(1):134-44
pubmed: 20887898
Pathobiology. 2018;85(1-2):72-84
pubmed: 29414818
Gut. 2017 Oct;66(10):1802-1810
pubmed: 27456153
Stem Cells. 2015 Jan;33(1):230-9
pubmed: 25187087
Cell Stem Cell. 2020 Jan 2;26(1):17-26.e6
pubmed: 31761724
Nat Commun. 2018 Nov 29;9(1):5079
pubmed: 30498242
Sci Rep. 2017 Mar 03;7:43249
pubmed: 28256524
Nature. 2015 Dec 10;528(7581):267-71
pubmed: 26633636
Nat Commun. 2016 Jun 10;7:11815
pubmed: 27283993
J Exp Med. 2008 Sep 29;205(10):2309-18
pubmed: 18809713
Nat Commun. 2017 Nov 1;8(1):1231
pubmed: 29093439
Mol Ther. 2008 Apr;16(4):698-706
pubmed: 18362927
Cold Spring Harb Protoc. 2011 Jan 01;2011(1):pdb.prot5546
pubmed: 21205846
Blood. 2013 Jul 25;122(4):523-32
pubmed: 23719303
Development. 2013 Jul;140(13):2835-46
pubmed: 23757414
Am J Clin Pathol. 2014 Dec;142(6):755-66
pubmed: 25389328
Nat Methods. 2011 Mar;8(3):253-9
pubmed: 21297621
Nat Methods. 2011 Mar;8(3):260-6
pubmed: 21297619
Cancer Res. 2016 Jun 15;76(12):3618-28
pubmed: 27197176
Nat Med. 2013 Dec;19(12):1661-6
pubmed: 24270544
Int J Cancer. 2019 Mar 15;144(6):1356-1366
pubmed: 30125350
Trends Cancer. 2022 Feb;8(2):98-109
pubmed: 34872888
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
Sci Rep. 2019 Mar 14;9(1):4542
pubmed: 30872730